Treatment of intestinal graft-versus-host disease using betamethasone enemas.
Transplantation
; 72(8): 1451-3, 2001 Oct 27.
Article
en En
| MEDLINE
| ID: mdl-11685119
Intestinal graft-versus-host disease (GVHD) can readily easily induce generalized metabolic disturbance that influences morbidity and mortality after allogeneic bone marrow transplantation. Although adding a new drug or increasing the doses of immunosuppressive agents will probably be effective for controlling intestinal GVHD, the systemic side effects of such therapy cannot be ignored. In this study, we used betamethasone retention enemas as a local treatment for eight patients with refractory and/or severe intestinal GVHD. Six of the eight patients showed improvement of diarrhea and/or abdominal pain, with a reduction in the stage of GVHD. When treatment with betamethasone enemas was continued for 10 to 27 days in the 6 responding patients, no severe toxicity was observed. One patient failed to respond to treatment and another could not tolerate the enemas. Despite some uncertainty regarding the indications and duration of treatment, betamethasone enemas seem to be a potential alternative method for the management of intestinal GVHD.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Betametasona
/
Trasplante de Médula Ósea
/
Enfermedad Injerto contra Huésped
/
Enfermedades Intestinales
/
Antiinflamatorios
Límite:
Adult
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Transplantation
Año:
2001
Tipo del documento:
Article
País de afiliación:
Japón
Pais de publicación:
Estados Unidos